Galmed Pharmaceuticals

GLMDPhase 3

Tel Aviv, IsraelFounded 2000galmedpharma.com

Galmed Pharmaceuticals is dedicated to addressing the significant unmet medical need in chronic liver diseases through its innovative small molecule platform. The company's primary asset, Aramchol, has undergone extensive clinical evaluation in NASH, including a Phase 2b/3 study (ARMOR), and is being repositioned for PSC. Despite clinical setbacks and strategic shifts, Galmed continues to explore the therapeutic potential of its lead compound while managing its financial resources to advance its pipeline.

Market Cap

$3.9M

Founded

2000

Employees

1-10

Focus

Biotech

GLMD · Stock Price

USD 0.60273.00 (-99.78%)

Historical price data

AI Company Overview

Technology Platform

Fatty Acid Bile Acid Conjugate (FABAC) platform, creating synthetic hybrid molecules designed to modulate liver fat metabolism and fibrosis through oral administration.

Pipeline Snapshot

13 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
Aramchol free acid + Placebo	Nonalcoholic Steatohepatitis (NASH)	Phase 3
Aramchol	Fatty Liver	Phase 2
Aramchol meglumine	Primary Sclerosing Cholangitis	Phase 2
Aramchol + Placebo	Gallstones	Phase 2
Aramchol + Midazolam + Atorvastatin	Healthy	Phase 1

Funding History

Total raised: $55M

PIPE$18MUndisclosedNov 15, 2019

IPO$25MUndisclosedFeb 15, 2014

Series A$12MUndisclosedSep 15, 2010

Opportunities

A successful proof-of-concept in the Phase 2a PSC trial could validate Aramchol's mechanism in a new, high-need rare disease, potentially leading to partnership opportunities and a focused development path.

Positive data may also open exploration into other cholestatic or fibrotic liver conditions.

Risk Factors

The company faces existential clinical risk from the ongoing PSC trial, severe financial constraints with a low market capitalization, and strategic risk as it is dependent on a single asset that previously failed in a larger indication.

Competitive Landscape

In PSC, Galmed competes with companies like Genfit/Ipsen (elafibranor) and others developing norUDCA and anti-integrin therapies. Differentiation hinges on Aramchol's unique FABAC mechanism and its potential for an improved tolerability profile compared to full FXR agonists.